scholarly journals Inhibitor of DNA binding 2 is a novel therapeutic target for stemness of head and neck squamous cell carcinoma

2017 ◽  
Vol 117 (12) ◽  
pp. 1810-1818 ◽  
Author(s):  
Woo Jin Bae ◽  
Bon Seok Koo ◽  
Sang Hyuk Lee ◽  
Jin Man Kim ◽  
Young Soo Rho ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Dna Binding ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Therapeutic Target ◽  
Neck Squamous Cell Carcinoma ◽  
Inhibitor Of Dna Binding ◽  
Novel Therapeutic

scholarly journals The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma

2009 ◽  
Vol 69 (7) ◽  
pp. 3021-3031 ◽  
Author(s):  
Tanguy Y. Seiwert ◽  
Ramasamy Jagadeeswaran ◽  
Leonardo Faoro ◽  
Varalakshmi Janamanchi ◽  
Vidya Nallasura ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Tyrosine Kinase ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Receptor Tyrosine Kinase ◽  
Therapeutic Target ◽  
Neck Squamous Cell Carcinoma ◽  
Met Receptor Tyrosine Kinase ◽  
Novel Therapeutic

scholarly journals X-linked FHL1 as a novel therapeutic target for head and neck squamous cell carcinoma

Oncotarget ◽  
2016 ◽  
Vol 7 (12) ◽  
pp. 14537-14550 ◽  
Author(s):  
Wei Cao ◽  
Jiannan Liu ◽  
Ronghui Xia ◽  
Lu Lin ◽  
Xu Wang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Therapeutic Target ◽  
Neck Squamous Cell Carcinoma ◽  
Novel Therapeutic

scholarly journals A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Aneesha Radhakrishnan ◽  
Vishalakshi Nanjappa ◽  
Remya Raja ◽  
Gajanan Sathe ◽  
Vinuth N. Puttamallesh ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Signaling Pathways ◽  
Cell Lines ◽  
Squamous Cell ◽  
Therapeutic Target ◽  
Neck Squamous Cell Carcinoma ◽  
Dual Specificity ◽  
Hnscc Cell

Abstract Despite advances in clinical management, 5-year survival rate in patients with late-stage head and neck squamous cell carcinoma (HNSCC) has not improved significantly over the past decade. Targeted therapies have emerged as one of the most promising approaches to treat several malignancies. Though tyrosine phosphorylation accounts for a minority of total phosphorylation, it is critical for activation of signaling pathways and plays a significant role in driving cancers. To identify activated tyrosine kinase signaling pathways in HNSCC, we compared the phosphotyrosine profiles of a panel of HNSCC cell lines to a normal oral keratinocyte cell line. Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) was one of the kinases hyperphosphorylated at Tyr-321 in all HNSCC cell lines. Inhibition of DYRK1A resulted in an increased apoptosis and decrease in invasion and colony formation ability of HNSCC cell lines. Further, administration of the small molecular inhibitor against DYRK1A in mice bearing HNSCC xenograft tumors induced regression of tumor growth. Immunohistochemical labeling of DYRK1A in primary tumor tissues using tissue microarrays revealed strong to moderate staining of DYRK1A in 97.5% (39/40) of HNSCC tissues analyzed. Taken together our results suggest that DYRK1A could be a novel therapeutic target in HNSCC.

Abstract 1017: Id-1 gene and protein as therapeutic target for head and neck squamous cell carcinoma

2014 ◽  
Author(s):  
Ryuichi Murase ◽  
Sean McAllister ◽  
Yohei Fujita ◽  
Tomoki Sumida ◽  
Koichi Nakashiro ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Therapeutic Target ◽  
Neck Squamous Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document